MAZE (Maze Therapeutics) Total Payout Ratio: 2.14 (As of Aug. 15, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MAZE Maze Therapeutics Inc MAZE
16 GF Score
Price $27.20
! 3 Warning Signs
View Full Analysis

What is Maze Therapeutics Total Payout Ratio?

Maze Therapeutics MAZE -1.63% 16 Total Payout Ratio is 2.14 as of Aug. 15, 2026. GuruFocus rates MAZE with a GF Score™ of 16/100. The stock has 3 warning signs investors should review.

Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income.

Maze Therapeutics's current Total Payout Ratio is 2.14.

Maze Therapeutics Total Payout Ratio Related Terms

Maze Therapeutics Total Payout Ratio Historical Data

* Premium members only.

The historical data trend for Maze Therapeutics's Total Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Maze Therapeutics Total Payout Ratio Chart

Maze Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Total Payout Ratio
0.00 0.00 0.00 2.06

Maze Therapeutics Quarterly Data
Dec22 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Payout Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.09 4.63 0.01 0.00 3.28

MAZE vs NTLA, RXRX, SEPN: Total Payout Ratio Comparison

For the Biotechnology subindustry, Maze Therapeutics's Total Payout Ratio, along with its competitors' market caps and Total Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Maze Therapeutics Total Payout Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Maze Therapeutics's Total Payout Ratio distribution charts can be found below:

* The bar in red indicates where Maze Therapeutics's Total Payout Ratio falls into.


MAZE
16GF Score
Maze Therapeutics Inc MAZE
Total Payout Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Maze Therapeutics Total Payout Ratio Calculation

Total Payout Ratio is a measurement showing the proportion of earnings a company pays shareholders in the form of dividends and net stock repurchases.

Maze Therapeutics's Total Payout Ratio for the fiscal year that ended in Dec. 2025 is calculated as

Total Payout Ratio=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Net Income
=- (0 + 270.275 + 0) / -131.12
=2.06

Maze Therapeutics's Total Payout Ratio for the quarter that ended in Jun. 2026 is calculated as

Total Payout Ratio=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Net Income
=- (0 + 146.657 + 0) / -44.727
=3.28

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Payout Ratio →
What does a Total Payout Ratio of 2.14 mean?
Maze Therapeutics (MAZE) has a Total Payout Ratio of 2.14 as of Aug. 15, 2026. Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income. View historical data on Maze Therapeutics and its competitors.
Is Maze Therapeutics' Total Payout Ratio too high?
Maze Therapeutics' current Total Payout Ratio is 2.14. Overall, Maze Therapeutics has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Maze Therapeutics' Total Payout Ratio compare to NTLA and RXRX?
Maze Therapeutics' Total Payout Ratio of 2.14 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Payout Ratio for a Biotechnology company?
A good Total Payout Ratio depends on the Biotechnology industry context. However, Total Payout Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Payout Ratio mean?
A high Total Payout Ratio can signal that a stock is expensive relative to its fundamentals. Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income. View historical data on Maze Therapeutics and its competitors. Maze Therapeutics's current Total Payout Ratio is 2.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Maze Therapeutics stock overvalued right now?
Maze Therapeutics (MAZE) has a current Total Payout Ratio of 2.14. The current Total Payout Ratio is 2.14. Maze Therapeutics' overall GF Score™ is 16/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Payout Ratio calculated?
Total Payout Ratio is calculated from a company's financial statements. For Maze Therapeutics (MAZE), the current Total Payout Ratio is 2.14 as of Aug. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Maze Therapeutics Business Description

Address 171 Oyster Point boulevard, Suite 300, South San Francisco, CA, USA, 94080
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.
16GF Score

Get the complete analysis for MAZE

Total Payout Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$27.20
Price